Fund moves

Merck (MRK): Perpetual Ltd reduced its stake -270K shares

Perpetual Ltd reduced its stake in Merck, per its Q3 2025 13F.

554K
Shares reported · -270K vs prior quarter
0.58%
Disclosed portfolio weight
$46.5M
Reported value
Holdings as of
Sep 30, 2025
Filed
Oct 10, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Sep 26, 2024CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  2. Oct 29, 2024CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  3. Mar 19, 2025CongressDisclosed sale of MRK — reported range $15,001 - $50,000
  4. Jun 24, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  5. Jul 11, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
  6. Aug 4, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
  7. Aug 5, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  8. Aug 14, 2025CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
  9. Aug 28, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  10. Sep 19, 2025FDAFDA drug approval: Keytruda Qlex
  11. Sep 19, 2025FDAFDA drug approval: Keytruda Qlex
  12. Sep 23, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000

What came next

  1. Oct 15, 2025FDAFDA drug approval: Bla761495
  2. Oct 24, 2025FDAFDA drug approval: Winrevair
  3. Oct 30, 2025Company filing · Form 8-K · ResultsReported its results
  4. Nov 3, 2025InsiderOfficer sold ~$720K of MRK shares in the open market
  5. Nov 10, 2025InsiderOfficer sold ~$616K of MRK shares in the open market
  6. Nov 13, 2025CongressDisclosed partial sale of MRK — reported range $1,001 - $15,000
  7. Nov 18, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  8. Nov 21, 2025FDAFDA drug approval: Keytruda
  9. Nov 21, 2025FDAFDA drug approval: Keytruda Qlex
  10. Dec 12, 2025FDARecall: Merck Emend (aprepitant) for oral suspension, 125 mg, Single-Dose Kit, Rx Only, Manufactured for: Merck Sharpe & Dohme LLC, Rahway, NJ 07065, USA, Manufactured…
  11. Dec 12, 2025FDARecall: Noxafil Powdermix (posaconazole) for Delayed-Release Oral Suspension, 300 mg, 8 packets per carton, Rx Only, Manufactured for: Merck Sharp & Doohme LLC, Rahway…
  12. Dec 18, 2025CongressDisclosed sale of MRK — reported range $1,001 - $15,000
  13. Dec 19, 2025CongressDisclosed purchase of MRK — reported range $1,001 - $15,000
  14. Jan 13, 2026Federal contract · $96K obligatedDepartment of Veterans Affairs awarded Merck: $96K obligated to date
  15. Jan 27, 2026FDAFDA drug approval: Noxafil
  16. Jan 27, 2026FDAFDA drug approval: Noxafil
  17. Feb 3, 2026Company filing · Form 8-K · ResultsReported its results
  18. Feb 4, 2026Insider · 4 peopleInsiders: 6 sales (~$13.2M)
  19. Feb 5, 2026InsiderOfficer sold ~$2.44M of MRK shares in the open market
  20. Feb 6, 2026Insider · 3 peopleInsiders: 3 sales (~$7.0M)
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Merck

For Merck, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 3 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MRK page.

How this filing works

Explore the data

Common questions

What does this filing report about Merck (MRK) stock?

Perpetual Ltd reduced its stake in Merck, per its Q3 2025 13F. Now 554K shares, $46.5M reported value, 0.58% of disclosed portfolio.

When did it happen, and when was it made public?

Holdings as of: Sep 30, 2025. Filed: Oct 10, 2025.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Form 13F-HR, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Merck recently?

For Merck, OQRO holds 3 insider filings (SEC Form 4 or Form 144), 3 Congress trade reports, 3 fund holdings reports (13F) and 2 federal contract awards dated in the last 90 days. They are listed on the MRK page.

Does this mean MRK stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Merck

Everything OQRO holds on this company is on its MRK page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data